Portfolio Companies – Page 33 – BioScience Managers

AVITA Medical Announces Presentation of RECELL® System Effectiveness and Safety at Eastern Great Lakes Burn Conference

27th September 2018/in Avita Medical

Clinical results demonstrate point-of-care regenerative medicine technology benefits in treatment of second- and third-degree burns using Spray-On Skin™ Cells Valencia, Calif., USA, and Melbourne, Australia, 27 September 2018 — AVITA Medical (ASX: AVH, OTCQX:AVMXY), a global regenerative medicinecompany, today announced that the results from two U.S. pivotalclinical trials demonstrating the effectiveness and clinical benefits of […]

Interim results for the six months ended 30 June 2018

26th September 2018/in Destiny Pharma

Destiny Pharma plc (“Destiny Pharma” or the “Company”) Interim results for the six months ended 30 June 2018 Clinical progress and pipeline expansion in dermal infections; well-funded through to H2 2020 Brighton, United Kingdom – 26 September 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development […]

Destiny Pharma announces appointment of Chief Medical Officer

26th September 2018/in Destiny Pharma

Destiny Pharma plc (“Destiny” or “the Company”) Dr Jesús González brings extensive experience in the clinical development of anti-infectives, as the Company prepares to initiate a Phase 2b trial for lead asset Brighton, United Kingdom – 26 September 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial […]

AVITA Medical Announces Receipt of $1 Million Research and Development Tax Credit

26th September 2018/in Avita Medical

Valencia, Calif., USA, and Melbourne, Australia, 26 September 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has received a Research and Development Tax Incentive cash rebate from the Australian Tax Office in the amount of A$1.0 million for the year ending 30 June 2017. The R&D […]

AmpliPhi Biosciences to Present Clinical Case Series Data at IDWeek 2018

24th September 2018/in Armata Pharmaceuticals

Professor Jonathan Iredell to present data from AmpliPhi Biosciences’ ongoing expanded access program for bacteriophage product candidates AB-SA01 (targeting S. aureus) and AB-PA01 (targeting P. aeruginosa) Monday, September 24, 2018 6:50 am EDT PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics […]

AVITA Medical Announces FDA Approval of the RECELL® System for the Treatment of Severe Burns in the U.S.

20th September 2018/in Avita Medical

Point-of-care regenerative medicine technology approved to treat secondand third-degree burns using Spray-On Skin™ Cells product U.S. market launch planned for 4th calendar quarter 2018. Target market for burns approximates USD $200 million Valencia, Calif., USA, and Melbourne, Australia, 21 September 2018 — AVITA Medical (ASX: AVH, OTCQX:AVMXY), a global regenerative medicine company, today announced that […]

AmpliPhi Biosciences Announces Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-PA01 Targeting Pseudomonas Aeruginosa Infections

18th September 2018/in Armata Pharmaceuticals

The FDA is in general agreement with the design of two proposed randomized clinical trials of AB-PA01, hospital-acquired and ventilator-associated pneumonia (HAP/VAP) due to P. aeruginosa and for P. aeruginosa bacteremia, and no additional preclinical or clinical data are required to proceed with both trials Based on the positive FDA feedback, AmpliPhi intends to seek […]

AmpliPhi Biosciences Announces Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-SA01

17th September 2018/in Armata Pharmaceuticals

FDA is in general agreement with the design of two proposed randomized clinical trials of AB-SA01, for Staphylococcus aureus bacteremia and prosthetic joint infections, and no additional preclinical or clinical data are required to proceed with both trials AmpliPhi expects to initiate one of these clinical trials in early 2019 AmpliPhi continues to investigate if […]

AmpliPhi Biosciences Announces Updated Positive Clinical Results for its Expanded Access Program

17th September 2018/in Armata Pharmaceuticals

21 patients at 7 hospitals, with serious or life-threatening infections not responding to antibiotics, have now been treated with AB-SA01 (targeting S. aureus) or AB-PA01 (targeting P. aeruginosa) under AmpliPhi’s expanded access program Over 1,000 doses of bacteriophage product candidates, AB-SA01 or AB-PA01, have been administered as part of the expanded access program since mid-2017 […]

Biopharma Company Arecor raises £6m for revolutionary diabetes treatments

10th September 2018/in Arecor

10 September 2018 – Arecor, the UK-based biopharmaceutical formulation company, has raised £6 million from new and existing investors to develop groundbreaking pharmaceutical drugs to transform the treatment of diabetes. The fundraising was led by Calculus Capital, Albion Capital, and Downing Ventures. BioScience Managers Limited, the international healthcare investment firm, advised Downing Ventures. Through the […]